These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 2874190)

  • 21. Glutamine, glutamine synthetase and Huntington's disease.
    Carter CJ
    Lancet; 1981 Jun; 1(8235):1427-8. PubMed ID: 6113388
    [No Abstract]   [Full Text] [Related]  

  • 22. Angiotensin-converting enzyme, enkephalinase A and aminopeptidases in the breakdown of enkephalin--studies in cell cultures.
    Lentzen H; Reinsch I; Linke J
    Clin Exp Hypertens A; 1984; 6(10-11):1829-32. PubMed ID: 6099767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease.
    Dure LS; Young AB; Penney JB
    Ann Neurol; 1991 Dec; 30(6):785-93. PubMed ID: 1665055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Monoamine oxidase activity in brain regions and organs of patients with Parkinson's disease and Huntington's disease and serum MAO activity of patients with Huntington's disease as compared with neurologically healthy individuals (author's transl)].
    Schneider G; Oepen H; von Wedel HR
    Arch Psychiatr Nervenkr (1970); 1981; 230(1):5-15. PubMed ID: 6455104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitochondrial defect in Huntington's disease caudate nucleus.
    Gu M; Gash MT; Mann VM; Javoy-Agid F; Cooper JM; Schapira AH
    Ann Neurol; 1996 Mar; 39(3):385-9. PubMed ID: 8602759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
    Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
    Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regional distribution of choline acetyltransferase in the human brain: changes in Huntington's chorea.
    Aquilonius SM; Eckernås SA; Sundwall A
    J Neurol Neurosurg Psychiatry; 1975 Jul; 38(7):669-77. PubMed ID: 125784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multimodal imaging biomarkers in premanifest and early Huntington's disease: 30-month IMAGE-HD data.
    D JF; Stout JC; Poudel G; Churchyard A; Chua P; Egan GF; Georgiou-Karistianis N
    Br J Psychiatry; 2016 Jun; 208(6):571-8. PubMed ID: 26678864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease.
    Dawbarn D; De Quidt ME; Emson PC
    Brain Res; 1985 Aug; 340(2):251-60. PubMed ID: 2862959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease.
    Mazziotta JC; Phelps ME; Pahl JJ; Huang SC; Baxter LR; Riege WH; Hoffman JM; Kuhl DE; Lanto AB; Wapenski JA
    N Engl J Med; 1987 Feb; 316(7):357-62. PubMed ID: 2949152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuronal distribution in the putamen in Huntington's disease.
    Roos RA; Pruyt JF; de Vries J; Bots GT
    J Neurol Neurosurg Psychiatry; 1985 May; 48(5):422-5. PubMed ID: 3158722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of glutamate decarboxylase in post-mortem brain tissue in Huntington's chorea.
    Iversen LL; Bird ED; Mackay AV; Rayner CN
    J Psychiatr Res; 1974; 11():255-6. PubMed ID: 4282387
    [No Abstract]   [Full Text] [Related]  

  • 33. Glutamine-, glutamine synthetase-, glutamate dehydrogenase- and pyruvate carboxylase-immunoreactivities in the rat dorsal root ganglion and peripheral nerve.
    Miller KE; Richards BA; Kriebel RM
    Brain Res; 2002 Aug; 945(2):202-11. PubMed ID: 12126882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [SPECT studies with 99mTc-HMPAO in Huntington's chorea patients].
    Botsch H; Oepen G; Deuschl G; Wolff G
    Rofo; 1987 Dec; 147(6):666-8. PubMed ID: 2827263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease.
    Boussicault L; Alves S; Lamazière A; Planques A; Heck N; Moumné L; Despres G; Bolte S; Hu A; Pagès C; Galvan L; Piguet F; Aubourg P; Cartier N; Caboche J; Betuing S
    Brain; 2016 Mar; 139(Pt 3):953-70. PubMed ID: 26912634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced glutamic-acid-decarboxylase activity of post-mortem brain in Huntington's chorea.
    Bird ED; Mackay AV; Rayner CN; Iversen LL
    Lancet; 1973 May; 1(7812):1090-2. PubMed ID: 4122011
    [No Abstract]   [Full Text] [Related]  

  • 37. Nuclear membrane indentations in Huntington's chorea.
    Roos RA; Bots GT
    J Neurol Sci; 1983 Sep; 61(1):37-47. PubMed ID: 6226764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kainic acid binding in human caudate nucleus: effect of Huntington's disease.
    Henke H
    Neurosci Lett; 1979 Oct; 14(2-3):247-51. PubMed ID: 161000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abnormalities of neurotransmitter enzymes in Huntington's chorea.
    Wu JY; Bird ED; Chen MS; Huang WM
    Neurochem Res; 1979 Oct; 4(5):575-86. PubMed ID: 40150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitors of GABA metabolism: implications for Huntington's disease.
    Schwarcz R; Bennett JP; Coyle JT
    Ann Neurol; 1977 Oct; 2(4):299-303. PubMed ID: 152600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.